Abstract:Although Nature's antisense approaches are clearly impressive, this Perspectives article focuses on the experimental uses of antisense reagents (ASRs) for control of biological processes. ASRs comprise antisense oligonucleotides (ASOs), and their catalytically active counterparts ribozymes and DNAzymes, as well as small interfering RNAs (siRNAs). ASOs and ribozymes/DNAzymes target RNA molecules on the basis of Watson-Crick base pairing in sequence-specific manner. ASOs generally result in destruction of the target RNA by RNase-H mediated mechanisms, although they may also sterically block translation, also resulting in loss of protein production. Ribozymes and DNAzymes cleave target RNAs after base pairing via their antisense flanking arms. siRNAs, which contain both sense and antisense regions from a target RNA, can mediate target RNA destruction via RNAi and the RISC, although they can also function at the transcriptional level. A considerable number of ASRs (mostly ASOs) have progressed into clinical trials, although most have relatively long histories in Phase I/II settings. Clinical trial results are surprisingly difficult to find, although few ASRs appear to have yet established efficacy in Phase III levels. Evolution of ASRs has included: (a) Modifications to ASOs to render them nuclease resistant, with analogous modifications to siRNAs being developed; and (b) Development of strategies to select optimal sites for targeting. Perhaps the biggest barrier to effective therapies with ASRs is the "Delivery Problem." Various liposomal vehicles have been used for systemic delivery with some success, and recent modifications appear to enhance systemic delivery, at least to liver. Various nanoparticle formulations are now being developed which may also enhance delivery. Going forward, topical applications of ASRs would seem to have the best chances for success. In summary, modifications to ASRs to enhance stability, improve targeting, and incremental improvements in delivery vehicles continue to make ASRs attractive as molecular therapeutics, but their advance toward the bedside has been agonizingly slow.

Therapeutic Antisense Oligonucleotides in Oncology: From Bench to Bedside

Antisense oligonucleotides: a novel Frontier in pharmacological strategy

The Challenges and Strategies of Antisense Oligonucleotide Drug Delivery

Clinical Applications of Antisense Oligonucleotides in Cancer: A Focus on Glioblastoma

Drug Discovery Perspectives of Antisense Oligonucleotides

Unveiling the potential of antisense oligonucleotides: Mechanisms, therapies, and safety insights

Therapeutic Antisense Oligonucleotides Are Coming of Age

Imaging-Assisted Antisense Oligonucleotide Delivery for Tumor-Targeted Gene Therapy

Transcript-Targeted Therapy Based on RNA Interference and Antisense Oligonucleotides: Current Applications and Novel Molecular Targets

Antisense Oligonucleotide-Based Therapy of Viral Infections

Antisense Oligonucleotides: The State of the Art

The application of antisense oligonucleotides in disease treatment

Antitumoral RNA‐targeted oligonucleotide therapeutics: the third pillar after small molecule inhibitors and antibodies

RNA-Based Therapeutics: Past, Present and Future Prospects, Challenges in Cancer Treatment

ANTISENSE OLIGONUCLEOTIDES: FROM DESIGN TO THERAPEUTIC APPLICATION

Bioconjugated oligonucleotides: recent developments and thera-eutic applications

Antisense applications for biological control

Precision Anti-Cancer Medicines by Oligonucleotide Therapeutics in Clinical Research Targeting Undruggable Proteins and Non-Coding RNAs

RNA Targeting Therapeutics: Molecular Mechanisms of Antisense Oligonucleotides as a Therapeutic Platform

Recent insights into the functions and mechanisms of antisense RNA: emerging applications in cancer therapy and precision medicine

Advancing Cancer Treatments: The role of oligonucleotides-based therapies in driving progress